Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Ligand to Hold Fourth Quarter Results Conference Call on February 20
Ligand to Present at BIO CEO and Investor Conference on February 12
Ligand Partner Pfizer Submits NDA for Fablyn(R)
Ligand Pharmaceuticals Awarded U.S. Patent for LGD-4665
Ligand Earns $1 Million Milestone Payment as GlaxoSmithKline Submits New Drug Application for PROMACTA(R) (eltrombopag)
Ligand Presents Positive LGD-4665 Phase I Clinical Trial Results at the American Society of Hematology Annual Meeting (ASH)
Ligand Pharmaceuticals Announces Third Quarter Results
Ligand to Hold Third Quarter Results Conference Call on November 8
Ligand to Present at Acumen BioFin Rodman & Renshaw Health Conference on November 5
Ligand Earns Milestone Payment as Wyeth Submits European Market Authorization for Bazedoxifene
Ligand Research Published in Journal of Medicinal Chemistry: LGD-2941 Shows Promise in Treating Muscle and Bone Loss
Ligand to Ring Opening Bell at NASDAQ Stock Market Ceremony
Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
